Q32 Bio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Q32 Bio Inc.
- Former names
- Homology Medicines, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- QTTB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001661998
- EIN
- 47-3468154
Board of directors
-
Albert Seymour · Director · See RemarksSince 2023
-
Alise Reicin · DirectorSince 2023
-
Arthur Tzianabos · DirectorSince 2023
-
David S. Grayzel · DirectorSince 2024
-
Diyong Xu · DirectorSince 2024
-
Isaac Manke · DirectorSince 2024
-
Jeffrey Poulton V · DirectorSince 2023
-
Jodie Pope Morrison · Director · CEOSince 2024
-
Kathleen Laporte · DirectorSince 2024
-
Mark T. Iwicki · DirectorSince 2024
- Since 2023
-
Matthew R. Patterson · DirectorSince 2023
-
Steven Gillis · DirectorSince 2023
-
Sven Ante Lundberg · DirectorSince 2024
Chief executives
Jodie Pope Morrison
· CEO
Since March 2024
Director election results
Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.4%
-
96.5%
-
99.7%
Board connections
11 of this board's directors also sit on 21 other boards.
- via David S. Grayzel and Mark T. Iwicki
- via Matthew R. Patterson and Sven Ante Lundberg
- via Isaac Manke
- via Mary Thistle
- via Mary Thistle
- via Kathleen Laporte
- via Jeffrey Poulton V
- via Mary Thistle
- via Mary Thistle
- via Alise Reicin
- via Mark T. Iwicki
- via Mark T. Iwicki
- via Steven Gillis
- via Isaac Manke
- via Kathleen Laporte
- via Isaac Manke
- via Alise Reicin
- via Arthur Tzianabos
- via Steven Gillis
- via Alise Reicin
- via Sven Ante Lundberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $30,000,000
- 4 purchases by 2 insiders
- Sold, last 12 months
- $459,748
- 8 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 25, 2026 | Kalowski Lee Officer (CFO and President) | Open-market sale | −3,972 | $16.56 | $65,776 |
| Aug 25, 2026 | Jodie Pope Morrison Director, Officer (CEO) | Open-market sale | −9,845 | $16.56 | $163,033 |
| Aug 25, 2026 | Violette Shelia M. Officer (Chief Scientific Officer) | Open-market sale | −2,798 | $16.56 | $46,335 |
| Jul 16, 2026 | Kalowski Lee Officer (CFO and President) | Grant or award | +53,250 | — | — |
| Jul 16, 2026 | Jodie Pope Morrison Director, Officer (CEO) | Grant or award | +132,000 | — | — |
| Jul 16, 2026 | Violette Shelia M. Officer (Chief Scientific Officer) | Grant or award | +37,500 | — | — |
| Jun 30, 2026 | Isaac Manke Director | Option exercise | +53,521 | $2.80 | $149,859 |
| May 28, 2026 | Diyong Xu Director, 10% owner | Open-market purchase | +1,250,000 | $8.00 | $10,000,000 |
| May 28, 2026 | OrbiMed Capital GP VII LLC Director, 10% owner | Open-market purchase | +1,250,000 | $8.00 | $10,000,000 |
| May 28, 2026 | Diyong Xu Director, 10% owner | Open-market purchase | +625,000 | $8.00 | $5,000,000 |
| May 28, 2026 | OrbiMed Capital GP VII LLC Director, 10% owner | Open-market purchase | +625,000 | $8.00 | $5,000,000 |
| Feb 25, 2026 | Kalowski Lee Officer (CFO and President) | Open-market sale | −3,995 | $4.51 | $18,017 |
| Feb 25, 2026 | Jodie Pope Morrison Director, Officer (CEO) | Open-market sale | −9,896 | $4.51 | $44,631 |
| Feb 25, 2026 | Violette Shelia M. Officer (Chief Scientific Officer) | Open-market sale | −2,815 | $4.51 | $12,696 |
| Feb 24, 2026 | Violette Shelia M. Officer (Chief Scientific Officer) | Grant or award | +37,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.